In addition, an updated RMP should be submitted • when new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimization activities. • within 60 days of an important (pharmacovigilance or risk minimization) milestone being reached. • at the request of the EMEA.